

IN THE CLAIMS Please cancel claims 21 – 40 without disclaimer or prejudice, and subject to applicant's right to present these claims in a divisional application. The remaining pending claims of the application are set forth below in the Complete Listing of All Pending Claims.

COMPLETE LISTING OF ALL PENDING CLAIMS

1. (original) A process of treating oral leukoplakia lesions of humans in need of such treatment, the process comprising the step of applying topically to the leukoplakia lesion an effective amount of a clear aqueous formulation comprising:

water;

a water miscible pharmaceutically acceptable polyol;

a pharmaceutically acceptable unsaturated fatty acid ester;

a pharmaceutically acceptable surfactant, and

β -carotene, said β -carotene being in a micellized form within said formulation.

2. (original) A process in accordance with Claim 1 wherein the formulation additionally comprises a pharmaceutically acceptable anti-oxidant.

3. (original) A process in accordance with Claim 2 wherein the pharmaceutically acceptable anti-oxidant is d-alpha-tocopherol or a pharmaceutically acceptable derivative of d-alpha tocopherol having vitamin E activity.

4. (original) A process in accordance with Claim 1 wherein the formulation additionally comprises a compound having vitamin A activity.

5. (original) A process in accordance with Claim 1 wherein the surfactant is polyethoxylated castor oil.

6. (original) A process in accordance with Claim 1 wherein the polyol is glycerol.

7. (original) A process in accordance with Claim 1 wherein the unsaturated fatty acid ester is ethyl linoleate.

8. (original) A process in accordance with Claim 1 wherein the formulation is a gel.

9. (original) A process in accordance with Claim 8 comprising the steps of applying the gel to the leukoplakia lesion at least twice a day.

10. (original) A process in accordance with Claim 1 wherein the formulation comprises:

10 to 50 % by weight water;

5 to 40 % by weight of the water miscible pharmaceutically acceptable polyol;

1 to 20 % by weight of the pharmaceutically acceptable unsaturated fatty acid ester;

10 to 60 % by weight of the pharmaceutically acceptable surfactant, and

0.03 to 9.0 % by weight of β -carotene.

11. (original) A process in accordance with Claim 10 wherein the water miscible pharmaceutically acceptable polyol is glycerol;

the pharmaceutically acceptable unsaturated fatty acid ester is ethyl linoleate, and

the pharmaceutically acceptable surfactant is polyethoxylated castor oil.

12. (original) A process in accordance with Claim 1 wherein the formulation comprises:

20 to 40 % by weight water;

10 to 30 % by weight of the water miscible pharmaceutically acceptable polyol;

1 to 15 % by weight of the pharmaceutically acceptable unsaturated fatty acid ester;

20 to 40 % by weight of the pharmaceutically acceptable surfactant, and
0.3 to 3.0 % by weight of β -carotene.

13. (original) A process in accordance with Claim 12 wherein the water miscible pharmaceutically acceptable polyol is glycerol;

the pharmaceutically acceptable unsaturated fatty acid ester is ethyl linoleate, and

the pharmaceutically acceptable surfactant is polyethoxylated castor oil.

14. (original) A process in accordance with Claim 13 wherein the formulation additionally comprises d-alpha-tocopherol and a compound having vitamin A activity.

15. (original) A process in accordance with Claim 14 wherein the formulation is a gel.

16. (original) A process in accordance with Claim 15 comprising the steps of applying the gel to the leukoplakia lesion at least twice a day.

17. (original) A process in accordance with Claim 1 wherein the formulation comprises:

50 to 95 % by weight water;

1 to 10 % by weight of the water miscible pharmaceutically acceptable polyol;

0.01 to 2 % by weight of the pharmaceutically acceptable unsaturated fatty acid ester;

0.01 to 5 % by weight of the pharmaceutically acceptable surfactant, and

0.003 to 1.2 % by weight of β -carotene,

1 to 10 % by weight of a pharmaceutically acceptable sweetener;

0.01 to 2% of a pharmaceutically acceptable antibacterial agent;

d -alpha tocopherol or a pharmaceutically acceptable derivative of d-alpha tocopherol having vitamin E activity;

vitamin A palmitate or a pharmaceutically acceptable derivative of vitamin A palmitate having vitamin A activity;

a pharmaceutically acceptable chelating agent;
a pharmaceutically acceptable antifoaming agent;
a flavoring agent, and
a preservative.

18. (original) A process in accordance with Claim 17 wherein the water miscible pharmaceutically acceptable polyol is glycerol;
the pharmaceutically acceptable unsaturated fatty acid ester is ethyl linoleate;

the pharmaceutically acceptable surfactant is polyethoxylated castor oil;
the pharmaceutically acceptable sweetener is xylitol;
the pharmaceutically acceptable antibacterial agent is cetyl pyridinium chloride;

the pharmaceutically acceptable chelating agent is disodium EDTA, and
the preservative is sodium benzoate.

19. (original) A process in accordance with Claim 18 wherein the formulation is an oral rinse.

20. (original) A process in accordance with Claim 19 wherein the formulation comprises:

75 to 95 % by weight water;
2 to 7 % by weight of glycerol;
0.01 to 0.5 % by weight ethyl linoleate;
0.01 to 1 % by weight polyethoxylated castor oil;
0.003 to 10.6 % by weight of β -carotene,
2 to 7 % by weight of xylitol;
0.01 to 1 % of cetyl pyridinium chloride;
0.005 to 0.05 % by weight of disodium EDTA;
0.2 to 1.5 % by weight of flavoring agent, and

0.01 to 0.5 % by weight of sodium benzoate.

CLAIMS 21 – 40 (Cancelled)